Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Influenza virus vaccine strain

A technology of influenza virus and avian influenza virus, applied in the direction of antiviral agents, viruses/bacteriophages, biochemical equipment and methods, etc., can solve the problems of lack of virus replication ability, avoid vaccine production lag, increase combination mode, and selection range wide range of effects

Active Publication Date: 2014-03-05
CHINA AGRI UNIV
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The rearrangement method of the traditional genetic engineering rearrangement vaccine only directs the hemagglutinin (HA) and neuraminic acid (neuraminic acid, NA) genes of the epidemic strains to be combined with the human H1N1 influenza virus A / Puerto Rico / 8 / 34 (referred to as PR8) internal gene rearrangement (2+6), did not compare the replication of viruses with other gene rearrangement methods

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Influenza virus vaccine strain
  • Influenza virus vaccine strain
  • Influenza virus vaccine strain

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Example 1. Rescue and purification of recombinant virus using reverse genetic manipulation technology

[0051] 1. Extract the RNA of A / Chicken / Hebei / YT / 2010 and A / Puerto Rico / 8 / 34 viruses.

[0052] 2. Reverse transcription was carried out using the RNAs of the two viruses as templates respectively.

[0053] The reverse transcription system is as follows:

[0054]

[0055] Add the above-mentioned ingredients in turn to the reaction tube, mix well, and centrifuge briefly.

[0056] Wherein vRNA refers to the RNA of the virus obtained in step one.

[0057] Reverse transcription conditions: 42°C for 1h, 94°C for 5min.

[0058] The cDNA product after reverse transcription was used as a template for PCR reaction.

[0059] 3. PCR amplification

[0060] The PCR reaction system is as follows:

[0061]

[0062] Wherein the cDNA is the cDNA of the A / Chicken / Hebei / YT / 2010 or A / Puerto Rico / 8 / 34 virus obtained in step 2.

[0063] Add the above ingredients in sequence, cen...

Embodiment 2

[0174] Embodiment 2, passage, purification and identification of recombinant virus

[0175] One, the 18 strains of recombinant viruses that embodiment 1 obtains are carried out serial passage on MDCK cell, and specific method is as follows: the mixed solution that contains the cell of virus and supernatant is mixed with 10 respectively. -2 、10 -3 、10 -4 Infect MDCK cells at a dilution ratio (DMEM containing 1% double antibody), select the virus with the highest HA titer (that is, the highest dilution factor at which the virus can agglutinate red blood cells) at each dilution ratio, and then use the selected virus as Infect MDCK cells in the same way, and continuously select the virus with the highest HA titer (that is, the highest dilution factor at which the virus can agglutinate red blood cells) at each dilution. In this way, 18 strains of recombinant virus were continuously transmitted to the 10th generation.

[0176] 2. Plaque purification of passaged virus

[0177] (1...

Embodiment 3

[0191] Embodiment 3, passage poison TCID 50 / mL and determination of hemagglutination titer

[0192] 1. Preparation of MDCK monolayer cells

[0193] Transfer MDCK cells to a 96-well cell culture plate 24 hours before the experiment. When the cells grow to 70%-90%, remove the culture solution in the well with a 10mL pipette, wash the cells with PBS, discard the washing solution, and repeat the washing 3 times.

[0194] 2. Doubling dilution of virus solution

[0195] (1) Take out the purified virus solution of 18 strains obtained in Example 2 in a -80°C refrigerator 30 minutes before the experiment, put it in a 4°C refrigerator, and let it melt naturally.

[0196] (2) Each virus was sequentially diluted to 10 times with DMEM containing 1% double antibody. -8 , mark it.

[0197] (3) Store the doubly diluted virus solution on ice.

[0198] 3. Inoculate the virus

[0199] (1) Inoculate MDCK cells on a 96-well plate, inoculate 3 cell wells with each dilution of virus solution...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an influenza virus vaccine strain. The invention discloses a virus. The amino acid sequence of each of PB2 protein, PB1 protein, PA protein, NP protein, NA protein, M1 protein, M2 protein, NS1 protein, NS2 protein and HA protein are respectively shown as follows: SEQ ID No. 26, SEQ ID No. 34, SEQ ID No. 33, SEQ ID No. 21, SEQ ID No. 29, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 31, SEQ ID No. 32 and SEQ ID No. 16. The recombinant virus disclosed by the invention can be rapidly and stably proliferated in high yield. Compared with the method for preparing the vaccine by utilizing the chicken embryo, the recombinant virus has obvious advantage, and the inactivated vaccine of the recombinant virus can be used for protecting animals against the infection of influenza virus.

Description

technical field [0001] The present invention relates to an influenza virus vaccine strain. Background technique [0002] The H9N2 subtype avian influenza virus mainly infects chickens, ducks, turkeys, quails, wild ducks and other poultry, and can cause clinical symptoms such as low mortality and mild respiratory infections or decreased egg production rate. Although the H9N2 subtype avian influenza virus is a low-pathogenic avian influenza virus, it can cause a serious drop in the egg production of laying hens, and an increase in the combined respiratory disease and mortality rate of broiler chickens and young chickens, often causing serious economic losses. . It is worth noting that the H9N2 subtype avian influenza virus can not only infect birds, but also break through the interspecies barrier and infect mammals and humans without going through an intermediate host. Since the first case of human infection with H9N2 subtype avian influenza was discovered in the world in 19...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N7/01A61K39/145A61P31/16C12R1/93
Inventor 孙怡朋刘金华张谞霄沈晔
Owner CHINA AGRI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com